Tradestie Institutional Equity Comparison Engine

FATE vs TAK โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-16 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

TAK Overall Edge

TAK Captures Institutional Edge (4โ€“0 Pillars ยท 8โ€“1 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) (TAK) driven by superior Valuation, Growth & Margin, Momentum & Technical, Options & Structure. Fundamentally, FATE trades at N/M Forward P/E with -1495.4% operating margin (+9.2% YoY revenue) versus TAK at 12.7x Forward P/E and 16.6% operating margin (+6.7% YoY). In options structure, FATE sits in BREAKDOWN (20th %ile IV; Dealer Gamma Walls on Pro) against TAK sits in UNCLASSIFIED (5th %ile IV; Dealer Gamma Walls on Pro).

Valuation Winner TAK
FATE N/M vs TAK 12.7x Fwd P/E
Growth & Margin Winner TAK
Op Margin -1495.4% vs 16.6% ยท YoY +9.2% vs +6.7%
Momentum & Technical Winner TAK
1Y +12.9% vs +51.8% ยท 52W Pos 8% vs 97%
Options & Structure Winner TAK
BREAKDOWN (20th %ile IV) vs UNCLASSIFIED (5th %ile IV)
FATE NASDAQ
Fate Therapeutics, Inc.
Biological Products, (No Disgnostic Substances)
$1.12
-12.5% 1D
Market Cap $162.9M
1M Return -37.43%
1Y Return +12.87%
Forward P/E N/M
Unified AI Score
43.0 / 100 HOLD
Tech 25.0 Fund 47.0 Flow 67.0 Mom 55.0
TAK NYSE
Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)
Pharmaceutical Preparations
$21.61
+0.86% 1D
Market Cap $67.5B
1M Return +9.89%
1Y Return +51.79%
Forward P/E 12.7x
Unified AI Score
48.0 / 100 HOLD
Tech 43.0 Fund 44.0 Flow 50.0 Mom 40.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: FATE +12.87% TAK +51.79% Spread: +38.92 pp (TAK Lead)

Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant Revenue ($B) & Operating Margin (%)
FATE TTM Op. Margin: -1495.4% TAK TTM Op. Margin: 16.6%
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on FATE vs TAK. Trailing 12-month operating profitability (FATE -1495.4% vs TAK 16.6%) and valuation multiples (FATE N/M vs TAK 12.7x Forward P/E) are benchmarked directly in Pillar 4 below.

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: FATE (1) vs TAK (8)
Institutional Metric FATE TAK Criterion Row Winner
Market Capitalization Scale $162.9M $67.5B Larger Scale TAK
Trailing P/E Ratio Valuation N/M N/M Lower Multiple Tie
Forward P/E Ratio Valuation N/M 12.7x Lower Multiple TAK
Revenue Growth (YoY) Growth +9.2% +6.7% Higher Growth FATE
Operating Margin (TTM) Profitability -1495.4% 16.6% Higher Margin TAK
Net Profit Margin Profitability 0.0% 0.9% Higher Margin TAK
Return on Equity (ROE) Capital Efficiency -60.8% 0.6% Higher ROE TAK
52-Week Range Position Momentum 8% ($1โ€“$3) 97% ($14โ€“$22) Stronger Trend TAK
Beta / 30D Volatility Risk Regime 2.16ฮฒ ยท 104% Vol -0.02ฮฒ ยท 22% Vol Lower Realized Risk TAK
Unified Institutional Score Composite Signal 43.0 / 100 (HOLD) 48.0 / 100 (HOLD) Higher Composite TAK

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full FATE vs TAK Buy Guide
FATE BREAKDOWN
118d in phase ยท OBV DISTRIBUTION
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 20th %ile
IV Regime Compressed (<25th %ile)
Live FATE Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
TAK UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 5th %ile
IV Regime Compressed (<25th %ile)
Live TAK Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither FATE nor TAK registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.